Payment overview · 2025
General Payments
$481.36
27 reported records · 14 companies
Healthcare provider profile · identity verified
Boris Gliner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PARMA, OH · NPI 1982648507
Verified facts
What the public records show
CMS Open Payments records show Boris Gliner, M.D. received $481.36 in general payments during 2025 across 27 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $116.66 | 24.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.74 | 14.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.82 | 13.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.97 | 7.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.92 | 6.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.72 | 5.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.16 | 4.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $18.98 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.18 | 3.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.02 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.59 | 3.5% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $16.47 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.54 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.59 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.36 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $116.66 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.89 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.54 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 308 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
308 | 96 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
308 | 96 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1069 | 284 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 957 | 266 |
| Atorvastatin Calcium | Atorvastatin Calcium | 824 | 232 |
| Losartan Potassium | Losartan Potassium | 698 | 192 |
| Potassium Chloride | Potassium Chloride | 620 | 172 |
| Metformin Hcl | Metformin Hcl | 493 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 486 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 85 |
| Jardiance | Empagliflozin | 308 | 96 |
| Furosemide | Furosemide | 291 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 69 |
| Omeprazole | Omeprazole | 223 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 220 | 64 |
| Allopurinol | Allopurinol | 198 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 175 | 49 |
| Lisinopril | Lisinopril | 170 | 48 |
| Atenolol | Atenolol | 168 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 41 |
| Simvastatin | Simvastatin | 151 | 41 |
| Glimepiride | Glimepiride | 143 | 35 |
| Eliquis | Apixaban | 140 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 132 | 36 |
| Clonidine Hcl | Clonidine Hcl | 127 | 30 |
| Methylprednisolone | Methylprednisolone | 123 | 100 |
| Gabapentin | Gabapentin | 120 | 29 |
| Donepezil Hcl | Donepezil Hcl | 119 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 31 |
| Farxiga | Dapagliflozin Propanediol | 98 | 16 |
| Warfarin Sodium | Warfarin Sodium | 93 | 21 |
| Synthroid | Levothyroxine Sodium | 88 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 28 |
| Carvedilol | Carvedilol | 83 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Klor-Con M20 | Potassium Chloride | 83 | 25 |
| Famotidine | Famotidine | 82 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 58 |
| Montelukast Sodium | Montelukast Sodium | 79 | 17 |
| Mirtazapine | Mirtazapine | 76 | 19 |
| Alendronate Sodium | Alendronate Sodium | 73 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 21 |
| Azithromycin | Azithromycin | 68 | 62 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 18 |
| Spironolactone | Spironolactone | 63 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 15 |
| Torsemide | Torsemide | 58 | 18 |
| Meloxicam | Meloxicam | 56 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 55 | 47 |
| Ozempic | Semaglutide | 55 | 12 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 12 |
| Ezetimibe | Ezetimibe | 48 | 15 |
| Trazodone Hcl | Trazodone Hcl | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Lidocaine | Lidocaine | 41 | 13 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | 15 |
| Valsartan | Valsartan | 35 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Nystatin | Nystatin | 28 | 18 |
| Ramipril | Ramipril | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Dulera | Mometasone/Formoterol | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.36 · 27 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AFREZZA, AREXVY, Arikayce, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, NURTEC ODT, PAXLOVID, PREVNAR 20, RECORLEV, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, VYNDAMAX, YUPELRI, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error